Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity

Oft, Martin · 2014 · Cancer Immunology Research

Abstract

Human cancer is characterized by deficits in antigen-specific immunity and intratumoral CD8+ T cells. On the other hand, inflammatory macrophages and mediators of chronic inflammation are highly prevalent in patients with late-stage cancer. Intratumoral T-cell deficiency and chronic inflammation have been linked independently to a poor prognosis in patients with cancer, and therapeutic approaches to overcome either pathology separately are in clinical testing. The anti-inflammatory cytokine interleukin (IL)-10 suppresses macrophage and proinflammatory Th17 T-cell responses by inhibiting the inflammatory cytokines IL-6 and IL-12/23. Corroborating the anti-inflammatory action of IL-10, deficiency in IL-10 leads to a stimulation of inflammatory responses and inflammatory bowel disease. The anti-inflammatory role of IL-10 fostered the assumption that IL-10 undermines the immune response to cancer. However, mice and humans deficient in IL-10 signaling develop tumors spontaneously and at high rates. Overexpression of IL-10 in models of human cancer or treatment with a pegylated IL-10 (PEG-IL-10) led to tumor rejection and long-lasting tumor immunity. IL-10 stimulates cytotoxicity of CD8+ T cells and the expression of IFN-γ in CD8+ T cells. IL-10–induced tumor rejections are dependent on the expression of IFN-γ and granzymes in tumor-resident CD8+ T cells and the upregulation of MHC molecules. These findings reconcile earlier clinical data, which showed that recombinant IL-10 increased IFN-γ and granzymes in the blood of treated individuals. PEG-IL-10 is therefore a unique therapeutic agent, which simultaneously stimulates antitumor immunity and inhibits tumor-associated inflammation. Cancer Immunol Res; 2(3); 194–9. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-13-0214

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 47 references

Cited by

See all 322

Metadata

Authors
Oft, M.
Affiliations
Author's Affiliation: ARMO BioSciences, Redwood City, California
Corresponding author
Oft, Martin
Venue
Cancer Immunology Research
Published
2014-03-01
Volume
2
Issue
3
Pages
194-199
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2114872225
Cited by
322
References
47
Citations by year
2026: 17 · 2025: 28 · 2024: 43 · 2023: 35 · 2022: 35 · 2021: 41 · 2020: 41 · 2019: 23 · 2018: 22 · 2017: 14 · 2016: 19 · 2015: 4
FWCI
5.63
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
IL-10, antitumor immunity, tumor inflammation, CD8+ T cells, interferon-gamma, granzymes, MHC expression, tumor rejection, IL-10 deficiency, interleukin-6, IL-12/23, Th17 cells, tumor-associated macrophages, cancer immunotherapy
MeSH terms
Animals, Humans, Inflammation, Interferon-gamma, Macrophages, Neoplasms, Polyethylene Glycols, Signal Transduction, Gene Expression Regulation, Neoplastic, Interleukin-10, CD8-Positive T-Lymphocytes, Mice, Granzymes, Th17 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. https://app.cochat.ai/papers/10.1158/2326-6066.cir-13-0214
The paper
Oft, M. (2014). IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-13-0214

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.